BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 32911532)

  • 21. HCK maintains the self-renewal of leukaemia stem cells via CDK6 in AML.
    Li Z; Wang F; Tian X; Long J; Ling B; Zhang W; Xu J; Liang A
    J Exp Clin Cancer Res; 2021 Jun; 40(1):210. PubMed ID: 34167558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of T-lymphocytic leukemia-initiating stem cells residing in a small subset of patients with acute myeloid leukemic disease.
    Risueño RM; Campbell CJ; Dingwall S; Levadoux-Martin M; Leber B; Xenocostas A; Bhatia M
    Blood; 2011 Jun; 117(26):7112-20. PubMed ID: 21562049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
    Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
    J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation.
    Tarighat SS; Santhanam R; Frankhouser D; Radomska HS; Lai H; Anghelina M; Wang H; Huang X; Alinari L; Walker A; Caligiuri MA; Croce CM; Li L; Garzon R; Li C; Baiocchi RA; Marcucci G
    Leukemia; 2016 Apr; 30(4):789-99. PubMed ID: 26536822
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
    Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
    Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Curcumin reduces expression of Bcl-2, leading to apoptosis in daunorubicin-insensitive CD34+ acute myeloid leukemia cell lines and primary sorted CD34+ acute myeloid leukemia cells.
    Rao J; Xu DR; Zheng FM; Long ZJ; Huang SS; Wu X; Zhou WH; Huang RW; Liu Q
    J Transl Med; 2011 May; 9():71. PubMed ID: 21595920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron Oxide Nanoparticles Combined with Cytosine Arabinoside Show Anti-Leukemia Stem Cell Effects on Acute Myeloid Leukemia by Regulating Reactive Oxygen Species.
    Dou J; Li L; Guo M; Mei F; Zheng D; Xu H; Xue R; Bao X; Zhao F; Zhang Y
    Int J Nanomedicine; 2021; 16():1231-1244. PubMed ID: 33633448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
    Bosman MC; Schuringa JJ; Quax WJ; Vellenga E
    Exp Hematol; 2013 Jun; 41(6):530-538.e1. PubMed ID: 23416210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LncRNA LINP1 regulates acute myeloid leukemia progression via HNF4α/AMPK/WNT5A signaling pathway.
    Shi J; Dai R; Chen Y; Guo H; Han Y; Zhang Y
    Hematol Oncol; 2019 Oct; 37(4):474-482. PubMed ID: 31325181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia.
    Hurtz C; Hatzi K; Cerchietti L; Braig M; Park E; Kim YM; Herzog S; Ramezani-Rad P; Jumaa H; Müller MC; Hofmann WK; Hochhaus A; Ye BH; Agarwal A; Druker BJ; Shah NP; Melnick AM; Müschen M
    J Exp Med; 2011 Oct; 208(11):2163-74. PubMed ID: 21911423
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia.
    Folkerts H; Hilgendorf S; Wierenga ATJ; Jaques J; Mulder AB; Coffer PJ; Schuringa JJ; Vellenga E
    Cell Death Dis; 2017 Jul; 8(7):e2927. PubMed ID: 28703806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML.
    Powell JA; Thomas D; Barry EF; Kok CH; McClure BJ; Tsykin A; To LB; Brown A; Lewis ID; Herbert K; Goodall GJ; Speed TP; Asou N; Jacob B; Osato M; Haylock DN; Nilsson SK; D'Andrea RJ; Lopez AF; Guthridge MA
    Blood; 2009 Nov; 114(23):4859-70. PubMed ID: 19805619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RUNX1 and CBFβ-SMMHC transactivate target genes together in abnormal myeloid progenitors for leukemia development.
    Zhen T; Cao Y; Ren G; Zhao L; Hyde RK; Lopez G; Feng D; Alemu L; Zhao K; Liu PP
    Blood; 2020 Nov; 136(21):2373-2385. PubMed ID: 32929473
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic and therapeutic relevance of c-FLIP in acute myeloid leukaemia.
    McLornan D; Hay J; McLaughlin K; Holohan C; Burnett AK; Hills RK; Johnston PG; Mills KI; McMullin MF; Longley DB; Gilkes A
    Br J Haematol; 2013 Jan; 160(2):188-98. PubMed ID: 23167276
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia.
    Mak PY; Mak DH; Ruvolo V; Jacamo R; Kornblau SM; Kantarjian H; Andreeff M; Carter BZ
    Br J Haematol; 2014 Nov; 167(3):376-84. PubMed ID: 25079338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia.
    Gentner B; Pochert N; Rouhi A; Boccalatte F; Plati T; Berg T; Sun SM; Mah SM; Mirkovic-Hösle M; Ruschmann J; Muranyi A; Leierseder S; Argiropoulos B; Starczynowski DT; Karsan A; Heuser M; Hogge D; Camargo FD; Engelhardt S; Döhner H; Buske C; Jongen-Lavrencic M; Naldini L; Humphries RK; Kuchenbauer F
    Exp Hematol; 2015 Oct; 43(10):858-868.e7. PubMed ID: 26163797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
    Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
    Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WT1 facilitates the self-renewal of leukemia-initiating cells through the upregulation of BCL2L2: WT1-BCL2L2 axis as a new acute myeloid leukemia therapy target.
    Zhou B; Jin X; Jin W; Huang X; Wu Y; Li H; Zhu W; Qin X; Ye H; Gao S
    J Transl Med; 2020 Jun; 18(1):254. PubMed ID: 32580769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51.
    Xie C; Drenberg C; Edwards H; Caldwell JT; Chen W; Inaba H; Xu X; Buck SA; Taub JW; Baker SD; Ge Y
    PLoS One; 2013; 8(11):e79106. PubMed ID: 24244429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia.
    Alachkar H; Santhanam R; Harb JG; Lucas DM; Oaks JJ; Hickey CJ; Pan L; Kinghorn AD; Caligiuri MA; Perrotti D; Byrd JC; Garzon R; Grever MR; Marcucci G
    J Hematol Oncol; 2013 Mar; 6():21. PubMed ID: 23497456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.